Company Overview and News

 
Hong Kong stocks end lower after Trump says he’s ‘not pleased’ with progress on US-China trade talks

2018-05-23 scmp
Hong Kong and mainland stocks fell on Wednesday after US President Donald Trump said he was “not pleased” with the progress of US-China trade talks, which had fuelled market optimism in recent days.
1898 HUNGF HNP 0902 1088

7
Bear of the Day: Consol Coal (CCR)

2018-03-28 zacks
The coal stocks had a stretch where they came out from underground and had their day in the sun. Lately, that hasn’t been the case as these stocks have come under pressure. Today’s Bear of the Day is a stock in that industry which has struggled to produce earnings growth. I’m talking about Zacks Rank #5 (Strong Sell) CONSOL Coal Resources (CCR - Free Report) .
1898 CCR TXN CNTE

6
Here's Why You Should Hold Natural Resource Partners Now

2018-03-27 zacks
Shares of Natural Resource Partners LP (NRP - Free Report) have outperformed the Coal industry in the last three months. The stock has returned 18.7% compared with the industry’s gain of 1.2 %. Natural Resource Partners carries a Zacks Rank #3 (Hold).
1898 FTI.WI NRP FMC CNTE SXC

 
Shenhua Profit Rises to 5-Year High as China Curbs Boost Coal - Bloomberg

2018-03-25 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
1898 YACAF YZC K3GD 1171 YZCHF YAL 1088

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...